Efficacious therapies for heart failure with reduced LVEF have been implemented following multiple pivotal randomized trials over the past 30 years, for example, beta-blockers, angiotensin-converting enzyme inhibitors, mineralocorticoid receptor antagonists, sodium-glucose transport protein 2 inhibitors, and cardiac resynchronization therapy.6 This evidence concerns the gene NR3C2 and heart failure.